Nektar Therapeutics
NKTR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,790 | $11,175 | $10,460 | $29,175 |
| % Growth | 5.5% | 6.8% | -64.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $7,977 |
| Gross Profit | $11,790 | $11,175 | $10,460 | $21,198 |
| % Margin | 100% | 100% | 100% | 72.7% |
| R&D Expenses | $27,252 | $29,886 | $30,480 | $28,745 |
| G&A Expenses | $16,070 | $17,072 | $24,346 | $17,135 |
| SG&A Expenses | $16,070 | $17,072 | $24,346 | $17,135 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $140 | $447 | $169 | -$39,030 |
| Operating Expenses | $43,462 | $47,405 | $54,995 | $6,850 |
| Operating Income | -$31,672 | -$36,230 | -$44,535 | $14,348 |
| % Margin | -268.6% | -324.2% | -425.8% | 49.2% |
| Other Income/Exp. Net | -$3,883 | -$5,551 | -$6,295 | -$7,346 |
| Pre-Tax Income | -$35,555 | -$41,781 | -$50,830 | $7,002 |
| Tax Expense | -$33 | -$188 | $52 | -$259 |
| Net Income | -$35,522 | -$41,593 | -$50,882 | $7,261 |
| % Margin | -301.3% | -372.2% | -486.4% | 24.9% |
| EPS | -1.87 | -2.95 | -3.62 | 0.52 |
| % Growth | 36.6% | 18.5% | -796.2% | – |
| EPS Diluted | -1.87 | -2.95 | -3.62 | 0.51 |
| Weighted Avg Shares Out | 14,087 | 14,087 | 14,062 | 13,982 |
| Weighted Avg Shares Out Dil | 14,087 | 14,087 | 14,062 | 14,240 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,819 | $1,969 | $2,874 | $2,942 |
| Interest Expense | $6,047 | $5,394 | $4,974 | $10,153 |
| Depreciation & Amortization | $196 | $214 | $426 | $332 |
| EBITDA | -$29,312 | -$33,787 | -$40,969 | $17,487 |
| % Margin | -248.6% | -302.3% | -391.7% | 59.9% |